Infectious diseases in systemic lupus erythematosus: Risk factors, management and prophylaxis

Bailliere's Best Practice and Research in Clinical Rheumatology

Volumn 16, Issue 2, 2002, Pages 281-291

  Fessler, Barri J ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Hepatitis; Herpes zoster; HIV; Infection; Systemic lupus erythematosus; Tuberculosis; Vaccination

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; AZATHIOPRINE; BCG VACCINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DIPHTHERIA TETANUS TOXOID; ETHAMBUTOL; FAMCICLOVIR; GABAPENTIN; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; ISONIAZID; LAMIVUDINE; LIDOCAINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TRICYCLIC ANTIDEPRESSANT AGENT; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ANTIVIRUS AGENT; RECOMBINANT ALPHA INTERFERON;

BACTERIAL INFECTION; CHRONIC DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG DOSE REGIMEN; DRUG SAFETY; GENETIC ASSOCIATION; HEPATITIS B; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION CONTROL; LIVER DYSFUNCTION; LIVER TOXICITY; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; VACCINATION; VIRUS REACTIVATION; DISEASE ACTIVITY; DNA POLYMORPHISM; HEPATITIS C; HEREDITY; HIGH RISK POPULATION; HOMOZYGOTE; INFECTION PREVENTION;

BACTERIAL INFECTIONS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OPPORTUNISTIC INFECTIONS; RISK FACTORS;

EID: 0036527946     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2001.0226     Document Type: Review

References (70)

1. Uramoto KM, Michet CJ Jr, Thumboo J et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis and Rheumatism 1999; 42: 46-50.
2. Ginzler E, Diamond H, Kaplan D et al. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis and Rheumatism 1978; 21: 37-44.
3. Nived O, Sturfelt G & Wollheim F. Systemic lupus erythematosus and infection: A controlled and prospective study including an epidemiological group. Quarterly Journal of Medicine 1985; 218: 271-287.
4. Rubin LA, Urowitz MD & Gladman DD. Mortality in systemic lupus erythematosus: The bimodal pattern revisited. Quarterly Journal of Medicine 1985; 55: 87-98.
5. Cervera R, Khamashta MA, Font J et al and the European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: A multicenter prospective study of 1,000 patients. Medicine 1999; 78: 167-175.
6. Hellman DB, Petri M & Whiting-O'Keefe Q. Fatal infections in SLE: Role of opportunistic organisms. Medicine 1987; 66: 341-348.
7. Petri M & Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: A prospective study of the Hopkins Lupus Cohort. Journal of Rheumatology 1992; 19: 1559-1565.
8. Zonana-Nacach A, Camargo-Coronel A, Yanez P et al. Infections in outpatients with systemic lupus erythematosus: A prospective study. Lupus 2001; 10: 505-510.
9. Petri M. Infection in systemic lupus erythematosus. Rheumatic Disease Clinics of North America 1998; 24: 423-456.
10. Lim E, Koh WH, Loh SF et al. Non-typhoidal salmonellosis in patients with systemic lupus erythematosus. A study of fifty patients and a review of the literature. Lupus 2001; 10: 87-92.
11. Van Der Straeten C, Wei N, Rothschild J et al. Rapidly fatal pneumococcal septicemia in systemic lupus erythematosus. Journal of Rheumatology 1987; 14: 1177-1180.
12. Kraus A, Cabral AR, Sifuentes-Osornio J et al. Listeriosis in patients with connective tissue diseases. Journal of Rheumatology 1994; 21: 635-638.
13. Kahl LE. Herpes zoster infections in systemic lupus erythematosus: Risk factors and outcome. Journal of Rheumatology 1994; 21: 84-86.
14. Ward MM & Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: The role of hospital experience in diagnosis and mortality. Arthritis and Rheumatism 1999; 42: 780-789.
15. Feng PH & Tan TH. Tuberculosis in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 1982; 41: 11-14.
16. Victorio-Navarra STG, Dy EER, Arroyo CG & Torralba TP. Tuberculosis among Filipino patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism 1996; 26: 628-634.
17. Balakrishnan C, Mangat G, Mittal G & Joshi VR. Tuberculosis in patients with systemic lupus erythematosus. Journal of the Association of Physicians of India 1998; 46: 682-683.
18. Klemperer P, Pollack AD & Baehr G. Pathology of disseminated lupus erythematosus. Archives of Pathology 1941; 32: 569.
19. Illiopoulos AG & Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism 1996; 25: 318-336.
20. Piliero P & Furie R. Functional asplemia in SLE. Seminars in Arthritis and Rheumatism 1990; 20: 185-189.
21. Bartholomew WR & Shanahan TC. Complement components and receptors: Deficiencies and disease associations. Immunology Series 1990; 52: 33-51.
22. Turner MW. Mannose-binding lectin (MBL) in health and disease. Immunobiology 1998; 199: 327-339.
23. Sullivan KE, Wooten C, Goldman D & Petri M. Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis and Rheumatism 1996; 39: 2046-2051.
24. Lau YL, Lau CS, Chan SY et al. Mannose-binding protein in Chinese patients with systemic lupus erythematosus. Arthritis and Rheumatism 1996; 39: 706-707.
25. Garred P, Madsen HO, Halberg P et al. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis and Rheumatism 1999; 42: 2145-2152.
26. Yee AMF, Ng SC, Sobel RE & Salmon JE. FcγRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus. Arthritis and Rheumatism 1997; 40: 1180-1182.
27. Wong KL. Pattern of SLE in Hong Kong Chinese: A cohort study. Scandinavian Journal of Rheumatology 1992; 21: 289-296.
28. Hernandez-Cruz B, Sifuentes-Osornio J, Ponce-De-Leon-Rosales S et al. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clinical and Experimental Rheumatology 1999; 17: 289-296.
29. Targeted tuberculin testing and treatment of latent tuberculosis infection: ATS/CDC Statement Committee on Latent Tuberculosis Infection. Morbidity and Mortality Weekly Report 2000; 49: 1-54.
30. Small PM & Fujiwara PI. Management of tuberculosis in the United States. New England Journal of Medicine 2001; 345: 189-200.
31. Manzi S, Kuller LH, Kutzer J et al. Herpes zoster in systemic lupus erythematosus. Journal of Rheumatology 1995; 22: 1254-1258.
32. Ishikawa O, Abe M & Miyachi Y. Herpes zoster in Japanese patients with systemic lupus erythematosus. Clinical and Experimental Dermatology 1999; 24: 327-328.
33. Moutsopoulos HM, Gallagher JD, Decker JL & Steinberg AD. Herpes zoster in patients with systemic lupus erythematosus. Arthritis and Rheumatism 1978; 21: 798-802.
34. Locksley RM, Flournoy N, Sullivan KM & Meyers JD. Infection with varicella-zoster virus after marrow transplantation. Journal of Infectious Diseases 1985; 152: 1172-1181.
35. Tyring S, Belanger R, Bezwoda W et al for the Collaborative Famciclovir Immunocompromised Study Group. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Investigation 2001; 19: 13-22.
36. Schmader K. Herpes zoster in older adults. Clinical Infectious Diseases 2001; 32: 1481-1486.
37. Lok AS, Lai CL, Wu PC et al. Hepatitis B virus infection in Chinese families in Hong Kong. American Journal of Epidemiology 1987; 126: 492-499.
38. Mandell GI et al. Principles and Practice of Infectious Diseases, 5th edn. Churchill Livingstone, 2000.
39. Bonafede RP, Van Staden M & Klemp P. Hepatitis B virus infection and liver function in patients with systemic lupus erythematosus. Journal of Rheumatology 1986; 13: 1050-1052.
40. Karakoc Y, Dilek K, Gullulu M et al. Prevalence of hepatitis C virus antibody in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 1997; 56: 570-571.
41. Kowdley KV, Subler DE, Scheffel J et al. Hepatitis C virus antibodies in systemic lupus erythematosus. Journal of Clinical Gastroenterology 1997; 25: 437-439.
42. Mok MY, Ng WL, Yuen MF et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clinical and Experimental Rheumatology 2000; 18: 363-368.
43. Ito S, Nakazono K, Murasawa A et al. Development of fulminant hepatitis B (precore variant mutant type after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patients). Arthritis and Rheumatism 2001; 44: 339-342.
44. Arend SM, Hagen EC, Kroes ACM et al. Activation of chronic hepatitis C virus infection by cyclophosphamide in a patient with cANCA-positive vasculitis. Nephrology, Dialysis, Transplantation 1995; 10: 884-887.
45. Albero MD, Rivera F, Merino E et al. Hepatitis C virus infection complicating lupus nephritis. Nephrology, Dialysis, Transplantation 1996; 11: 1342-1345.
46. Fukuyama S, Kajiwara E, Suzuki N et al. Systemic lupus erythematosus after α-interferon therapy for chronic hepatitis C: A case report and review of the literature. American Journal of Gastroenterology 2000; 95: 310-312.
47. Fox RA & Isenberg DA. Human immunodeficiency virus infection in systemic lupus erythematosus. Arthritis and Rheumatism 1997; 40: 1168-1172.
48. Furie R. Effects of human immunodeficiency virus infection on the expression of rheumatic illness. Rheumatic Disease Clinics of North America 1991; 17: 177-188.
49. Clutterbuck DJ, Watson J, De Ruiter A et al. Presence of HIV infection in patients diagnosed with systemic lupus erythematosus. Rheumatology 2000; 39: 1047-1048.
50. Diri E, Lipsky PE & Berggren RE. Emergence of systemic lupus erythematosus after initiation of highly active antiretroviral therapy for human immunodeficiency virus infection. Journal of Rheumatology 2000; 27: 2711-2714.
51. Savarino A, Gennero L, Sperber K & Boelaert JR. The anti-HIV-I activity of chloroquine. Journal of Clinical Virology 2001; 20: 131-135.
52. Alonso CM & Lozada CJ. Effects of IV cyclophosphamide on HIV viral replication in a patient with systemic lupus erythematosus. Clinical and Experimental Rheumatology 2000; 18: 510-512.
53. Avery RK. Vaccination of the immunosuppressed adult patient with rheumatologic disease. Rheumatic Disease Clinics of North America 1999; 25: 567-584.
54. Klippel JH, Karsh J, Stahl NI et al. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis and Rheumatism 1979; 22: 1321-1325.
55. Ayvazian LF & Badger TL. Disseminated lupus erythematosus occurring among student nurses. New England Journal of Medicine 1948; 88: 833-834.
56. Brown MA & Bertouch JV. Rheumatic complications of influenza vaccination. Australian and New Zealand Journal of Medicine 1994; 24: 572-573.
57. Ichikawa N, Takase S & Kogure K. Recurrent aseptic meningitis following influenza vaccination: A case of systemic lupus erythematosus. Rinsho Shinkeigaku 1983; 23: 570-576.
58. Williams GW, Steinberg AD, Reinertsen JL et al. Influenza immunization in systemic lupus erythematosus. A double blind trial. Annals of Internal Medicine 1978; 88: 729-734.
59. Ristow SC, Douglas RG & Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Annals of Internal Medicine 1978; 88: 786-789.
60. Brodman R, Gilfillan R, Glass D & Schur PH. Influenzal vaccine response in systemic lupus erythematosus. Annals of Internal Medicine 1978;88: 735-740.
61. Louie JS, Nies KM, Shoji KT et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Annals of Internal Medicine 1978; 88: 790-792.
62. Abu-Shakra M, Zalmanson S, Neumann L et al. Influenza virus vaccination of patients with systemic lupus erythematosus: Effects on disease activity. Journal of Rheumatology 2000; 27: 1681-1685.
63. Battafarano DF, Battafarano NJ, Larsen L et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis and Rheumatism 1998; 41: 1828-1834.
64. Senecal J-L, Bertrand C & Coutlee F. Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy: Comment on the article by Battafarano et al. Arthritis and Rheumatism 1999; 42: 1307-1308.
65. Maillefert JF, Tavernier C, Sibilia J & Vignon E. Exacerbation of systemic lupus erythematosus after hepatitis B vaccination: Comment on the article by Battafarano et al and the letter by Senecal et al. Arthritis and Rheumatism 2000; 43: 468-472.
66. Gartner S & Emlen W. Hepatitis B vaccination of SLE patients. Arthritis and Rheumatism 1996; S291.
67. Recommendations of the advisory committee on immunization practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence. Morbidity and Mortality Weekly Report 1993; 42: 1-18.
68. Recommendations of the advisory committee on immunization practices (ACIP): Prevention of pneumococcal disease. Morbidity and Mortality Weekly Report 1997; 46: 1-25.
69. Recommendations of the advisory committee on immunization practices (ACIP): Prevention and control of influenza. Morbidity and Mortality Weekly Report 1999; 48: 1-29.
70. Hernandez-Cruz B, Ponce-De-Leon-Rosales S, Sifuentes-Osornio J et al. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case control study. Clinical and Experimental Rheumatology 1999; 17: 81-87.